Ranolazine

Spécifications

95635-55-5Numéro CAS

620-450-7Numéro CE

N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamideNom IUPAC

C24H33N3O4Formule chimique

427.5 g/molMasse molaire

RANOLAZINE; 95635-55-5; Ranexa; CVT-303; RAN D; Ran4; RS-43285-003; (+-)-Ranolazine; ASPRUZYO; Ranolazina; DTXSID3045196; renolazine; NSC-759100; A6IEZ5M406; N-(2,6-DIMETHYLPHENYL)-4-[2-HYDROXY-3-(2-METHOXYPHENOXY)PROPYL]-1-PIPERAZINEACETAMIDE; DTXCID1025196; RS43285; N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide; 1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-; 1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-; ranolazinum; HCl, Ranolazine; N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)piperazin-1-yl)ethanimidic acid; N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}ethanimidic acid; ASPRUZYO SPRINKLE; RefChem:55969; Hydrochloride, Ranolazine; Dihydrochloride, Ranolazine; CHEBI:87681; C01EB18; 43285, RS; RS 43285193; RS 43285 193; N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)piperazin-1-yl)acetamide; N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide; 142387-99-3; C24H33N3O4; N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide; MFCD00864690; CHEBI:87690; NCGC00015897-02; (-)-Ranolazine; Latixa; CAS-95635-55-5; Ranexa (TN); Ranolazine [USAN]; SR-01000076216; Ranolazine (USAN/INN); UNII-A6IEZ5M406; Ranolazin; Ranolazine [USAN:INN:BAN]; HSDB 7924; KEG-1295; (+/-)-Ranolazine; Ranolazine (Ranexa)?; Ranolazine (Standard); Ranexa; CVT-303; RANOLAZINE [MI]; RANOLAZINE [INN]; RANOLAZINE [VANDF]; RANOLAZINE [MART.]; CHEMBL1404; RANOLAZINE [USP-RS]; RANOLAZINE [WHO-DD]; Lopac0_001062; BSPBio_002276; MLS002154149; RANOLAZINE [EMA EPAR]; SCHEMBL124665; SPECTRUM1505366; GTPL7291; orb1221636; orb1300599; Ranolazine - Bio-X trade mark; SCHEMBL7933344; RANOLAZINE [ORANGE BOOK]; HY-B0280R; GLXC-07953; HMS1922F16; HMS2090L09; HMS2093D21; HMS2098K06; HMS2230C19; HMS3369I08; HMS3655M12; HMS3715K06; HMS3884I10; HMS5080E09; Pharmakon1600-01505366; HY-B0280; PEA24680; SFA38799; STB80488; Tox21_110258; BDBM50173335; EBC-11221; NSC759100; NSC782305; s1799; AKOS015889500; Tox21_110258_1; AC-1673; CCG-205139; DB00243; FD61499; KS-1244; NSC 759100; NSC-782305; PB21724; SB13209; SDCCGSBI-0051032.P003; NCGC00015897-03; NCGC00015897-04; NCGC00015897-05; NCGC00015897-06; NCGC00015897-08; NCGC00015897-17; NCGC00015897-22; NCGC00095177-01; NCGC00095177-02; NCGC00095177-03; BD164322; SMR000857382; SBI-0051032.P002; NS00002495; SW197620-4; T6633; D05700; EN300-122384; AB00698532-11; AB00698532-13; AB00698532-14; AB00698532-15; AB00698532_16; AB00698532_17; AB00698532_18; F079440; Q907104; SR-01000076216-5; SR-01000076216-8; BRD-A97674275-001-01-9; BRD-A97674275-001-04-3; BRD-A97674275-001-10-0; BRD-A97674275-001-11-8; BRD-A97674275-300-03-1; Z68563450; Ranolazine Working Standard (Secondary Reference Standard); (+/-)-4-(2-Hydroxy-3-(o-methoxyphenoxy)propyl)-1-piperazineaceto-2',6'-xylidide; (+-)-N-(2,6-Dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-1-piperazineacetamide; (+/-)-1-(3-(2-Methoxyphenoxy)-2-hydroxypropyl)-4-(n-(2,6-dimethylphenyl)carbamoylmethyl)piperazine; (+/-)-N-(2,6-DIMETHYLPHENYL)-4-(2-HYDROXY-3-(2-METHOXYPHENOXY)PROPYL)-1-PIPERAZINEACETAMIDE; 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6-dimethylphenyl)aminocarbonylmethyl]piperazine; 1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)-, (+-)-; 1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-, (+/-)-; 1080496-58-7; N-(2,6-Dimethyl-phenyl)-2-{4-[2-hydroxy-3-(2-methoxy-phenoxy)-propyl]-piperazin-1-yl}-acetamide; N-(2,6-DIMETHYLPHENYL)-2-(4-((2RS)-2-HYDROXY-3-(2-METHOXYPHENOXY)PROPYL)PIPERAZIN-1-YL)ACETAMIDE; N-(2,6-Dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxy-phenoxy)propyl)piperazin-1-yl)acetamideSynonymes